PHASQ (PhaseBio Pharmaceuticals) Cash Conversion Cycle : 0.00 (As of Jun. 2022)

View and export this data going back to 2018. Start your Free Trial

What is PhaseBio Pharmaceuticals Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

PhaseBio Pharmaceuticals's Days Sales Outstanding for the three months ended in Jun. 2022 was 0.
PhaseBio Pharmaceuticals's Days Inventory for the three months ended in Jun. 2022 was .
PhaseBio Pharmaceuticals's Days Payable for the three months ended in Jun. 2022 was .
Therefore, PhaseBio Pharmaceuticals's Cash Conversion Cycle (CCC) for the three months ended in Jun. 2022 was 0.00.

PhaseBio Pharmaceuticals Cash Conversion Cycle Historical Data

The historical data trend for PhaseBio Pharmaceuticals's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhaseBio Pharmaceuticals Cash Conversion Cycle Chart

PhaseBio Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Cash Conversion Cycle

Get a 7-Day Free Trial

PhaseBio Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Apr24
Cash Conversion Cycle	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of PhaseBio Pharmaceuticals's Cash Conversion Cycle

For the Biotechnology subindustry, PhaseBio Pharmaceuticals's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PhaseBio Pharmaceuticals's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhaseBio Pharmaceuticals's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where PhaseBio Pharmaceuticals's Cash Conversion Cycle falls into.

Save Embed

;

Save Embed

;

PhaseBio Pharmaceuticals Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

PhaseBio Pharmaceuticals's Cash Conversion Cycle for the fiscal year that ended in Dec. 2021 is calculated as

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	0	+		-
	=	0.00

PhaseBio Pharmaceuticals's Cash Conversion Cycle for the quarter that ended in Jun. 2022 is calculated as:

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	0	+		-
	=	0.00

PhaseBio Pharmaceuticals (OTCPK:PHASQ) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.

Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.

PhaseBio Pharmaceuticals Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of PhaseBio Pharmaceuticals's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.

PhaseBio Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseBio Pharmaceuticals Inc (OTCPK:PHASQ) » Definitions » Cash Conversion Cycle

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Great Valley Parkway, Suite 30, Malvern, PA, USA, 19355

Website

https://www.phasebio.com

PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. The company is also developing its preclinical product candidate, PB6440, for treatment-resistant hypertension.

Executives

New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Glen Burkhardt	officer: VP, Human Resources	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY.,SUITE 30, MALVERN PA 19355
Jonathan Birchall	officer: Chief Commercial Officer	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PARKWAY, SUITE 30, MALVERN PA 19355
William D. Humphries	director	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Clay Thorp	director	C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Nancy J Hutson	director	64 MONTAUK AVENUE, STONINGTON CT 06378
Edmund Harrigan	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Caroline M Loewy	director	300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Van Den Broek Richard	director	73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Peter Justin Klein	director	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
David James Ballance	officer: VP, Research and Sci. Affairs	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Michael York	officer: VP, Corporate Development	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
John Sang Lee	officer: Chief Medical Officer	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Susan Elizabeth Arnold	officer: VP, Preclinical and Chem	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY DRIVE, SUITE 30, MALVERN PA 19355
Kristopher Hanson	officer: VP, Head of Legal	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355